Intranasal Modified Vacc-4x Gag Peptides With Endocine as Adjuvant

NCT01473810 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

24

Enrollment

OTHER

Sponsor class

Conditions

HIV Infection

Interventions

BIOLOGICAL: Vacc-4x low dose
BIOLOGICAL: Vacc-4x medium dose
BIOLOGICAL: Vacc-4x high dose
BIOLOGICAL: Zero dose

Sponsor

Oslo University Hospital

Collaborators

[object Object]
[object Object]